Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.791
Abstract: We report pharmacokinetics, pharmacodynamics, and safety of a novel anti‐CD28 domain antibody antagonist (lulizumab pegol) in healthy subjects following single‐ or multiple‐dose administration. A minimal anticipated biological effect level approach was used to select a…
read more here.
Keywords:
antibody antagonist;
anti cd28;
novel anti;
domain antibody ... See more keywords